Claudia joined Anaveon from Celgene/BMS in Neuchâtel, where she led, in Europe and Japan, a multicohort, registrational trial evaluating liso-cel, a CD19 directed CAR-T cell therapy in B cell lymphoma with successful submission and recent approval granted across regions. Claudia moved from clinic to industry in 2011, at Takeda then Debiopharm in Lausanne. She has 10+ years pharma experience, conducting global clinical trials in early and late-stage solid tumors and hemato-oncology. She obtained her medical degree and oncology board certification in Lausanne after completion of her doctoral thesis in the immunobiology of fibrosis at the University of Geneva.

Share Share It FB TW GP